Chronic Urticaria

Dermatology
3
Pipeline Programs
4
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 4 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

UP
UCB PharmaBelgium - Brussels
1 program
1
LevocetirizinePhase 41 trial
Active Trials
NCT01250652Completed24Est. Mar 2013
Genentech
GenentechCA - Oceanside
1 program
1
OmalizumabPhase 4Monoclonal Antibody1 trial
Active Trials
NCT01701583Completed10Est. Oct 2017
Teva
TevaIsrael - Petach Tikva
1 program
1
TEV-45779Phase 31 trial
Active Trials
NCT04976192Completed608Est. Apr 2024
Novartis
NovartisBASEL, Switzerland
2 programs
AWARE - Chronic UrticariaN/A1 trial
Non Interventional StudyN/A1 trial
Active Trials
NCT02435238Completed180Est. Sep 2017
NCT02626221Completed497Est. Mar 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GenentechOmalizumab
UCB PharmaLevocetirizine
TevaTEV-45779
NovartisNon Interventional Study
NovartisAWARE - Chronic Urticaria

Clinical Trials (5)

Total enrollment: 1,319 patients across 5 trials

NCT01701583GenentechOmalizumab

Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria

Start: Apr 2013Est. completion: Oct 201710 patients
Phase 4Completed
NCT01250652UCB PharmaLevocetirizine

Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses

Start: Mar 2011Est. completion: Mar 201324 patients
Phase 4Completed
NCT04976192TevaTEV-45779

Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

Start: Aug 2021Est. completion: Apr 2024608 patients
Phase 3Completed
NCT02626221NovartisNon Interventional Study

A Worldwide Antihistamine-Refractory Chronic Urticaria Patient Evaluation in Latin America and Canada (AWARE-LACan)

Start: Dec 2014Est. completion: Mar 2018497 patients
N/ACompleted
NCT02435238NovartisAWARE - Chronic Urticaria

AWARE - Chronic Urticaria

Start: Sep 2014Est. completion: Sep 2017180 patients
N/ACompleted

Related Jobs in Dermatology

MSL/Senior MSL, Dermatology - Tampa, Florida

AbbVie
Remote
6h ago

(Senior) Außendienstmitarbeiter Dermatology (all genders) - Region Thüringen

AbbVie
Remote
6h ago

(Senior) Außendienstmitarbeiter Dermatology (all genders) - Region Thüringen

AbbVie
Remote
6h ago

Regional Sales Trainer - Dermatology (Central / West Regions)

AbbVie
Remote
7h ago

Regional Sales Trainer - Dermatology (Northeast / Southeast Regions)

AbbVie
Remote
7h ago

Delegado Especialista Ventas Dermatología (Inmunología)

AbbVie
Remote
11h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space

Related Indications

Dermatitis, Atopic(42)Hidradenitis Suppurativa(30)Chronic Spontaneous Urticaria(21)Alopecia Areata(17)Hidradenitis Suppurativa (HS)(10)Vitiligo(9)Rosacea(6)Pruritus(5)Androgenetic Alopecia(5)Uremic Pruritus(5)